RCN Congress Congress
Congress 2023 is coming to Brighton! The RCN’s annual event will be heading south this spring and taking up residence at the Brighton Centre on the seafront from 14-18 May.
Read moreCongress 2023 is coming to Brighton! The RCN’s annual event will be heading south this spring and taking up residence at the Brighton Centre on the seafront from 14-18 May.
Read moreThrombosis UK is pleased to announce that entries are now being accepted for the charity’s prestigious VTE Awards.
The awards celebrate outstanding practice across healthcare services working to prevent and embed effective management of venous thromboembolism (VTE).
The Award ceremony will be held in The Houses of Parliament on Wednesday 29th November, hosted by Lyn Brown MP, Chair of the All Party Parliamentary Group on Thrombosis.
Read moreThese will be supported by new Q&A interviews with leading VTE clinicians being shared everyday during NTW!
Read moreFind out more.
Read morewegegergeg
Read moreThe BSHT committee are delighted to announce that the BSHT Annual Scientific meeting 2023 will be held as a face to face meeting from Wednesday 25 - Friday 27 January 2023
Read moreThe date for National Thrombosis Week has been released. Running between the 1st - 7th May 2023.
Read moreThis is session 2 of the 2 part series: Improving the safe and effective use of DOACs
Read moreThis is session 1 of the 2 part series: Improving the safe and effective use of DOACs.
Anticoagulants are linked to more deaths and severe harm than any other medicine, being involved in 2 out of 9 medicines related claims that end in damages. The DOACs are now the most popular anticoagulants, with almost 1 million patients in England taking these medicines. This number continues to grow on an annual basis. Whilst the DOACs require less frequent monitoring than older anticoagulants, it is essential that is still carried out, and in particular, renal function, as their dose needs to be optimised to CrCl. Recent national data has shown that 15% of patients taking DOACs in England may be on the wrong dose in relation to their renal function, putting them at an increased risk of harm.
In this first webinar of a 2-part series we will set the national safety context around the use of DOACs, in addition to what is happening that might influence this issue in England. We will also share current guidance on the appropriate dosing, monitoring and review of the DOACs.
Read more18-20 October 2022
Optimising prevention, management and outcomes
Read more